Cargando…
Differential expression of apoptotic genes PDIA3 and MAP3K5 distinguishes between low- and high-risk prostate cancer
BACKGROUND: Despite recent progress in the identification of genetic and molecular alterations in prostate cancer, markers associated with tumor progression are scarce. Therefore precise diagnosis of patients and prognosis of the disease remain difficult. This study investigated novel molecular mark...
Autores principales: | Pressinotti, Nicole Chui, Klocker, Helmut, Schäfer, Georg, Luu, Van-Duc, Ruschhaupt, Markus, Kuner, Ruprecht, Steiner, Eberhard, Poustka, Annemarie, Bartsch, Georg, Sültmann, Holger |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2807430/ https://www.ncbi.nlm.nih.gov/pubmed/20035634 http://dx.doi.org/10.1186/1476-4598-8-130 |
Ejemplares similares
-
Classification across gene expression microarray studies
por: Buness, Andreas, et al.
Publicado: (2009) -
Characterization of Transcriptional Changes in ERG Rearrangement-Positive Prostate Cancer Identifies the Regulation of Metabolic Sensors Such as Neuropeptide Y
por: Massoner, Petra, et al.
Publicado: (2013) -
A Comparative Analysis of Punicalagin Interaction with PDIA1 and PDIA3 by Biochemical and Computational Approaches
por: Paglia, Giuliano, et al.
Publicado: (2021) -
Aromatic sulphonamides of aziridine-2-carboxylic acid derivatives as novel PDIA1 and PDIA3 inhibitors
por: Zelencova-Gopejenko, D., et al.
Publicado: (2023) -
ERp57/PDIA3: new insight
por: Chichiarelli, Silvia, et al.
Publicado: (2022)